Abstract：Objective To investigate the clinical features, diagnosis and treatment of glucose transporter 1 deficiency syndrome (GLUT1-DS), as well as the diagnostic value of movement disorders. Methods The clinical data of four children with GLUT1-DS were collected, and their clinical features, treatment, and follow-up results were analyzed. Results There were two boys and two girls, with an age of onset of 2-15 months. Clinical manifestations included movement disorders, seizures, and developmental retardation. Seizures were the cause of the first consultation in all cases. The four children all had persistent ataxia, dystonia, and dysarthria; two had persistent tremor, two had paroxysmal limb paralysis, and two had eye movement disorders. Paroxysmal symptoms tended to occur in fatigue state. All four children had reductions in the level of cerebrospinal fluid glucose and its ratio to blood glucose, as well as SLC2A1 gene mutations. The four children were given a ketogenic diet, at a ketogenic ratio of 2:1 to 3:1, and achieved complete remission of paroxysmal symptoms within 5 weeks. Conclusions GLUT1-DS should be considered for epileptic children with mental retardation and motor developmental delay complicated by various types of movement disorders. The ketogenic diet is effective at a ketogenic ratio of 2:1 to 3:1 for the treatment of GLUT1-DS.
JI Xin-Na,XU Cui-Juan,GAO Zhi-Jie et al. Glucose transporter 1 deficiency syndrome:features of movement disorders, diagnosis and treatment[J]. CJCP, 2018, 20(3): 209-213.
Pearson TS, Akman C, Hinton VJ, et al. Phenotypic spectrum of glucose transporter type 1 deficiency syndrome[J]. Curr Neurol Neurosci Rep, 2013, 13(4):342.
[4]
Akman CI, Yu J, Alter A, et al. Diagnosing glucose transporter 1 deficiency at initial presentation facilitates early treatment[J]. J Pediatr, 2016, 171:220-226.
[5]
Pons R, Collins A, Rotstein M, et al. The spectrum of movement disorders in Glut-1 deficiency[J]. Mov Disord, 2010, 25(3):275-281.
[6]
Pellegrin S, Cantalupo G, Opri R, et al. EEG findings during "paroxysmal hemiplegia" in a patient with GLUT1-deficiency[J]. Eur J Paediatr Neurol, 2017, 21(3):580-582.
[7]
Pearson TS, Pons R, Engelstad K, et al. Paroxysmal eye-head movements in GLUT1 deficiency syndrome[J]. Neurology, 2017, 88(17):1666-1673.
[8]
De Giorgis V, Varesio C, Baldassari C, et al. Atypical manifestations in Glut1 deficiency syndrome[J]. J Child Neurol, 2016, 31(9):1174-1180.
[9]
Pong AW, Geary BR, Engelstad KM, et al. Glucose transporter type I deficiency syndrome:epilepsy phenotypes and outcomes[J]. Epilepsia, 2012, 53(9):1503-1510.
[10]
Suls A, Mullen SA, Weber YG, et al. Early-onset absence epilepsy caused by mutations in the glucose transporter GLUT1[J]. Ann Neurol, 2009, 66(3):415-419.
[11]
Brockmann K. The expanding phenotype of GLUT1-deficiency syndrome[J]. Brain Dev, 2009, 31(7):545-552.
Klepper J. GLUT1 deficiency syndrome in clinical practice[J]. Epilepsy Res, 2012, 100(3):272-277.
[14]
Fajardo M, Cirillo ML. Understanding the spectrum of SLC2A1-associated disorders[J]. Pediatr Neurol Briefs, 2017, 31(2):4.
[15]
Fujii T, Ito Y, Takahashi S, et al. Outcome of ketogenic diets in GLUT1 deficiency syndrome in Japan:A nationwide survey[J]. Brain Dev, 2016, 38(7):628-637.
[16]
Kass HR, Winesett SP, Bessone SK, et al. Use of dietary therapies amongst patients with GLUT1 deficiency syndrome[J]. Seizure, 2016, 35:83-87.
